tional pharmacoepidemiology, because the selection bias derived from inclusion of prevalent users is minimized and the associations are more consistent with those from randomized trials (3) . Of interest, in an analysis of the Johns Hopkins Precursors Study by Klag and colleagues (4) in which the baseline age was younger than 30 years (that is, closer to an incident user design), there was a strong association between coffee use and cardiovascular events in multivariable analyses.
The risk for residual confounding is also worth mentioning. Socially conditioned behaviors, such as coffee intake, are particularly challenging and subject to confounding by socioeconomic status (SES). As with studies of moderate alcohol consumption, these behaviors are strongly prevalent in groups with higher SES, and higher SES in itself is a protective factor for health outcomes (5) . Although the authors did adjust for education, SES is a complex, latent construct for which proxies (such as education, income, or occupation) are often measured erroneously when measured at all and may not fully capture the effect of SES. Of note, Gunter and colleagues' (1) sensitivity analysis assessing robustness to residual confounding found that a risk factor with a hazard ratio of 1.50 (within the realm of the feasible effect sizes of poverty [5] ) needs only a 20% difference in the confounder between groups.
Because of these limitations, we believe that the reports of these studies in the lay press may have exaggerated their causal significance. Future research on coffee intake and health should aim to include younger persons and use more comprehensive measurements of SES. TO THE EDITOR: Gunter and colleagues (1) report that persons in the highest quartile of coffee consumption have a 7% to 10% higher risk for death than nonconsumers of coffee in a study of more than 450 000 adults from 10 European countries. However, this association was reversed after adjustment for covariates. In the multivariable-adjusted model, high coffee consumption is related to a 12% and 7% lower mortality risk in men and women, respectively. The authors suggest that coffee may confer health benefits.
Miguel Cainzos-Achirica, MD, MPH
The instability of the results in relation to covariate adjustments raised our concern about the validity of this conclusion. We would like to elaborate on the possibility that the findings may be attributable to bias and confounding by unmeasured or imprecisely measured risk factors. For example, some diseases and symptoms related to hypersensitivity or intolerance to coffee may also be linked to shorter life expectancy, contributing to a spurious association between coffee consumption and mortality (www.evidence.nhs.uk). Socioeconomic health determinants, such as income, occupational position, and neighborhood characteristics, are related to coffee consumption (2) and mortality (2) (3) (4) . Such factors may have affected the results but were not controlled for in the analyses. This interpretation is consistent with the result that the relationship between coffee consumption and education (another socioeconomic health resource) was more marked in men than women, as was the association between coffee consumption and mortality (1) .
According to calculations of the E-value (5), a single confounder related to coffee consumption and mortality risk and with a hazard ratio of 1.5 could explain the 12% lower mortality in men with high coffee consumption; the corresponding hazard ratio in women would be 1.4. Thus, even minor uncontrolled risk and protective factors-including those listed heremay, in combination, bias Gunter and colleagues' findings (1). Indeed, Mendelian randomization analyses, which are more protected from bias and confounding than Gunter and colleagues' observational findings, do not support protective effects for high coffee consumption in relation to cardiovascular disease or all-cause mortality (3).
The National Institutes of Health, with support from the alcohol industry, is starting a $100 million clinical trial to definitively answer whether moderate alcohol consumption prevents heart attacks. Because coffee consumption is more widespread and possibly more amenable to change than alcohol consumption, a large-scale trial of this practice is equally justified to obtain definite conclusions about its health effects. 
Mika

IN RESPONSE:
We agree that the results of our analysis do not provide evidence for a causal relationship between coffee drinking and reduced risk for all-cause and cause-specific mortality. We unfortunately cannot control hyperbole generated by the lay press, although we made every effort to stress the limitations of observational analyses in our interactions with journalists. As suggested, a clinical trial could provide more definitive evidence on whether coffee drinking directly affects health, and we welcome such an initiative.
Dr. Cainzos-Achirica and colleagues and Drs. Kivimaki and Ferrie suggest that residual confounding by SES may have contributed to the observed inverse relationship between coffee consumption and mortality. As indicated, we used education level as a proxy for SES; although we agree that this factor is an imperfect measure of SES, it is a widely used indicator of latent SES and is strongly associated with mortality rates in the EPIC (European Prospective Investigation into Cancer and Nutrition) cohort (1) . Using education as a surrogate marker of SES allowed the classification of all participants (including those not working or retired); education level generally remains stable over a participant's lifespan and can be accurately recorded, allowing comparisons across the EPIC study. The inverse associations between coffee and mortality observed in our analysis were stable after we adjusted for education, and of note, coffee drinking across the 10 European countries was not related to education level or more common among those with healthier lifestyle habits. Further, although coffee drinking may have become more prevalent in such countries as the United Kingdom in recent years and could track with SES, these changes have not been observed in most other countries included in the study.
We cannot exclude the possibility that survivor bias may have influenced the observed relationship between coffee consumption and mortality. However, if survivor bias did significantly affect our results, we would expect this relationship to differ substantially by age. We did not detect any effect modification by age at recruitment categories (<45 years, 45 to 59 years, and ≥60 years; P for interaction = 0.94). Although this observation does not exclude an effect of survivor bias, it indicates that any such effect is unlikely to be large.
We fully acknowledge the limitations of our analysis and urge caution in the interpretation of the results. However, we also emphasize the striking consistency between our findings and those of several other large-scale studies done in the United States (2-4) and Asia (5). The effect of coffee drinking on health deserves further investigation. Statin Denial: An Internet-Driven Cult With Deadly Consequences TO THE EDITOR: Nissen's suggestion (1) that an Internetdriven cult is aimed at stopping the prescription of statins is ludicrous. Furthermore, his affirmation that myalgia is a nocebo effect is confounded by the fact that such an effect requires patients to know that it might happen, which-in my experience in a rheumatology clinic where I have seen many patients with statin myalgia-they mostly do not. As someone who myself experienced severe adverse effects from statins and who rigorously analyzes trial methods, I am affronted by the suggestion that I belong to a dangerous cult. I am unaware that a myalgic nocebo effect can be accompanied by a 4-fold increase in creatine kinase levels, which happened to me with statin use.
Short-term crossover trials are worthless for an effect that can persist for months or, in my case, years. I do not consider that an absolute risk reduction of less than 2% induced by a drug, as is the case with statins and that is quoted by Nissen, represents a statistically significant effect. I have noted that trials of proprotein convertase subtilisin/kexin type 9 inhibition have shown dramatic decreases in cholesterol levels without any change in cardiac mortality (and that, without explanation, 1 major trial was terminated early). I do not deny that statins have some effect; however, given this evidence, I consider this (undoubted but small) effect to be independent of their cholesterol-lowering properties. Moreover, Keys' original study on which the whole cholesterol-heart hypothesis is based results from selective data analysis, with data cherry picked to fit the hypothesis. I am concerned that the progenitors of recent trials have refused to submit their data for independent analysis and have received much of their funding from pharmaceutical companies that manufacture statins.
To deny these facts is unscientific. Skepticism is to denial as agnosticism is to atheism. Nissen should learn about the black swan theory and the null hypothesis; in the case of statins, so many facts flatly contradict the cholesterol-heart hypothesis that it can no longer be accepted. TO THE EDITOR: Nissen argues that not continuing a statin after an adverse event is unreasonable behavior, equivalent to membership in "a statin denial cult" (1) . This analysis fails to take into account some implications of what we might call the public health paradox. From an aggregate perspective, Nissen is right: Statins are effective at decreasing the risk for cardiovascular events in certain populations. However, from the perspective of the individual health care consumer, things look very different.
Andrew Bamji, MB
Taking any medication involves a certain amount of inconvenience and expense. Now add an adverse event, which the consumer attributes (rightly or wrongly) to the statin. The rational person might well ask, "How likely is it that this drug is benefiting me?" The answer, according to Nissen, is 59:1-that is, 60 persons in this high-risk cohort will have to use this drug to avoid 1 coronary event. This discovery will probably startle the consumer, who may conclude, "Out of every 60 persons who take this pill, 59 are getting nothing out of it. Therefore, the chances that I am benefiting from this drug are pretty low." Given these odds, it no longer seems unreasonable for the individual health care consumer to stop taking this drug.
IN RESPONSE: Dr. Bamji's comment reflects the typical perspective offered by statin denial cults. That he acknowledges membership in a notorious organization known as The International Network of Cholesterol Skeptics is not surprising. Inquisitive readers should visit the Web site of this pseudoscientific organization, which promotes a book entitled Fat and Cholesterol Don't Cause Heart Attacks and Statins Are Not the Solution (1). The Web site asks visitors, "Have you had any side effects from statin treatment?" and offers referral to a medical malpractice law firm. Such fringe organizations choose to ignore the massive body of evidence on the effects of statins on vascular disease, including the meta-analysis of randomized trials involving 170 000 patients by the Cholesterol Treatment Trialists' Collaboration (2). Dr. Bamji repeats antistatin zealots' frequent claim that the favorable clinical trial data on statins reflect collusion between drug manufacturers and academic authors funded to conduct clinical trials.
Dr. Davis suggests that the number needed to treat (NNT) for statins is not clinically significant and that it would therefore be reasonable for a patient to discontinue statins because many patients would observe no benefits. If we accept this logic, we would cease to administer most preventive therapies, which have similar NNTs to statins-including influenza vaccination, which has an NNT of 40 (3).
Drs. Bamji and Davis both ignore the scientific facts. In the meta-analysis by the Cholesterol Treatment Trialists' Collaboration, the annual rate for major vascular events in 21 placebo-controlled statin trials was reduced from 3.6% to 2.8% for each decrease in low-density lipoprotein cholesterol of 1 mmol/L (38.7 mg/dL) (relative risk, 0.78 [95% CI, 0.76 to 0.81]; P < 0.001). The observed event reduction translates to a 5-year NNT of approximately 25. The relative risk for coronary heart disease mortality in this meta-analysis was similar at 0.80 (CI, 0.73 to 0.86).
Dr. Bamji is of course correct that some patients experience adverse effects when they take statins. I never suggested that all statin-associated muscle symptoms represent the nocebo effect. In fact, I previously reported a randomized clinical trial that confirmed statin-induced muscle symptoms by a crossover design in a substantial fraction (approximately 40%) of patients with a strong history of statin intolerance (4 
IN RESPONSE:
The 2015 NSDUH questionnaire items about specific pain relievers focused exclusively on prescription opioids (1) . On the basis of data from this survey, 34% of civilian, noninstitutionalized adults in the United States reported having used at least 1 of these specific prescription opioids at least once in the past 12 months (Table) .
In addition to these specific prescription opioids, the NSDUH asked respondents, "In the past 12 months, have you used any other prescription pain reliever?" (1) . Most of the adults who reported doing so also reported having used 1 or more of the specific prescription opioids in the Table. Only approximately 3.8% of adults reported that they exclusively used "other prescription pain reliever" rather than the specific prescription opioids cited in the Table. "Other prescription pain reliever" could be a prescription opioid similar to any product specified in the Table or a nonopioid pain reliever. The NSDUH did not ask respondents to further specify the name of the prescription, a limitation that we should note.
The NSDUH did not cover homeless persons not living in shelters, active duty military personnel, or those residing in institutions. Homeless adults not living in shelters and adults in the criminal justice system or staying in long-term care hospitals or nursing homes have a much higher prevalence of prescription opioid use than civilian, noninstitutionalized adults (2, 3). Thus, the rate of prescription opioid use of 37.8% reported in our study is unlikely to be markedly overestimated.
As a comparison, by using data from the IMS Health Total Patient Tracker, we found that 63.2 million adults were dispensed opioids in U.S. outpatient retail pharmacies in 2015. This company used a proprietary algorithm to derive nationally projected estimates of the number of unique adult patients dispensed prescription opioids in such settings during that year (4) . These data do not include the approximately 6.9 million adults who reported having used opioids without a prescription at least once in 2015. Furthermore, the data from IMS do not include adults who obtained prescription opioids from nonprescription sources or from hospitals, clinics, and other nonretail settings. Therefore, the overall number of U.S. adults with prescription opioid use is expected to be much higher than the estimate based on outpatient retail pharmacy data only. Both our estimates based on data from the NSDUH (91.8 million persons) and outpatient retail pharmacies (63.2 million persons) consistently suggest a high prevalence of prescription opioid use among U.S. adults.
